In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The Pharmacology of Longevity: Peptide Edition (Part 1) BPC 157 Weight Loss: Evidence & Safety The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling